009290 — Kwangdong Pharmaceutical Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedSmall CapSuper Stock

Market Cap
KR₩236bn
Enterprise Value
KR₩353bn
Revenue
KR₩2tn

Annual income statement for Kwangdong Pharmaceutical Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	1,243,770	1,338,182	1,431,545	1,514,454	1,640,719
Cost of Revenue
Gross Profit	257,709	274,253	282,048	299,827	299,298
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	1,199,914	1,293,246	1,393,198	1,474,925	1,612,865
Operating Profit	43,856	44,936	38,347	39,529	27,854
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	62,951	34,329	36,291	49,019	57,325
Provision for Income Taxes
Net Income After Taxes	45,602	25,541	26,701	39,372	41,845
Minority Interest
Net Income Before Extraordinary Items
Net Income	45,370	24,019	24,174	36,966	40,481
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	45,370	24,032	24,174	36,966	40,481
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	1,148	583	584	1,003	997
Dividends per Share